Suppression of STAT3 and HIF-1 Alpha Mediates Anti-Angiogenic Activity of Betulinic Acid in Hypoxic PC-3 Prostate Cancer Cells

Jimin Shin*, Hyo-Jeong Lee*, Deok-Beom Jung, Ji Hoon Jung, Hyo-Jung Lee, Eun-Ok Lee, Seok Geun Lee, Beom Sang Shim, Seung Hoon Choi, Seong Gyu Ko, Kwang Seok Ahn, Soo-Jin Jeong*, Sung-Hoon Kim*

College of Oriental Medicine, Kyung Hee University, Seoul, South Korea

Abstract

Background: Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that regulates various cellular processes such as cell survival, angiogenesis and proliferation. In the present study, we examined that betulinic acid (BA), a triterpene from the bark of white birch, had the inhibitory effects on hypoxia-mediated activation of STAT3 in androgen independent human prostate cancer PC-3 cells.

Methodology/Principal Findings: BA inhibited the protein expression and the transcriptional activities of hypoxia-inducible factor-1α (HIF-1α) under hypoxic condition. Consistently, BA blocked hypoxia-induced phosphorylation, DNA binding activity and nuclear accumulation of STAT3. In addition, BA significantly reduced cellular and secreted levels of vascular endothelial growth factor (VEGF), a critical angiogenic factor and a target gene of STAT3 induced under hypoxia. Furthermore, BA prevented in vitro capillary tube formation in human umbilical vein endothelial cells (HUVECs) maintained in conditioned medium of hypoxic PC-3 cells, implying anti-angiogenic activity of BA under hypoxic condition. Of note, chromatin immunoprecipitation (ChiP) assay revealed that BA inhibited binding of HIF-1α and STAT3 to the VEGF promoter. Furthermore, silencing STAT3 using siRNA transfection effectively enhanced the reduced VEGF production induced by BA treatment under hypoxia.

Conclusions/Significance: Taken together, our results suggest that BA has anti-angiogenic activity by disturbing the binding of HIF-1α and STAT3 to the VEGF promoter in hypoxic PC-3 cells.

Introduction

Signal transducer and activator of transcription 3 (STAT3) is one of STAT protein family and constitutively active in a wide range of human cancer cells [1]. Activated STAT3 proteins by cytokines and growth factors form homo- or heterodimers, and then translocate from the cytoplasm to the nucleus, where they are binding to the promoter of various gene products involved in anti-apoptosis (bcl-2, bcl-xI, and survivin), proliferation (cyclin D1), and angiogenesis (vascular endothelial growth factor (VEGF)) [2]. Interestingly, recent studies reported that STAT3 is activated in response to hypoxia, a common feature of various solid tumors [3,4]. Activated STAT3 mediates the up-regulation of hypoxia inducible factor alpha (HIF-1α), a major regulator to adapt under hypoxic conditions by increasing its stability and transcriptional activity [5]. Thus, recently STAT3 and HIF-1α are attractive target molecules by natural compounds and herbal extracts in cancer research.

Betulinic acid (BA), initially reported as a human melanoma-specific inhibitor, is a triterpene mainly derived from the bark of the white birch (Betula pubescens) [6]. Recent evidences suggest the anti-cancer effects of BA [7,8], anti-inflammatory [9] and anti-viral [10] activities via various signaling pathways such as epidermal growth factor receptor (EGFR) [11], hedgehog [12], signal transducer and activator of transcription 3 (STAT3) [13] and nuclear factor-kappa B (NF-kB) [14]. Nonetheless, there is no evidence that BA mediates anti-cancer activity through inhibiting STAT3 signaling in solid tumors.

Thus, in the present study, we investigated the roles of STAT3 and HIF-1α in BA induced anti-angiogenic activity in hypoxic PC-3 prostate cancer cells by MTT assay, Western blotting, immunocytochemistry, ELISA and EMSA.

Results

Cytotoxic effect of betulinic acid (BA) against PC-3 cells

Cytotoxic effect of BA (Fig. 1) was evaluated by MTT assay. PC-3 cells were treated with various concentrations of BA (0, 12.5, 25, 50 or 100 μM) for 24 h. Cell viability was reduced to
Effects of betulinic acid (BA) on hypoxia-induced angiogenesis

Hypoxia is one of angiogenesis inducers through HIF-1α activation [18]. Thus, the inhibitory effect of BA was evaluated on hypoxia-mediated angiogenesis. VEGF, a critical angiogenesis factor [19], was evaluated at the secreted cellular and protein levels by ELISA and Western blotting, respectively. BA significantly reduced VEGF production in a dose-dependent manner by ELISA (Fig. 4A). Consistently, BA attenuated VEGF protein expression in a dose-dependent manner by Western blotting (Fig. 4B).

Additionally, HUVEC tube formation assay, which is known as a typical angiogenesis in vitro model, was performed to confirm anti-angiogenic effect of BA on hypoxia-mediated angiogenesis. VEGF was used as a positive control of angiogenesis induction. HUVECs mixed with the supernatants from PC-3 cells were cultured in the absence or presence of BA under hypoxia. As shown in Fig. 4C, hypoxia-induced tube formation was prevented by BA treatment in PC-3 cells while clear tube formation was exhibited in untreated control under hypoxia, suggesting that BA inhibits hypoxia-mediated angiogenesis.

Effects of betulinic acid (BA) on the binding of STAT3 and HIF1α to VEGF promoter in hypoxic PC-3 cells

Recent studies revealed that STAT3 activation is directly linked to the transcriptional regulation of VEGF by binding to the VEGF promoter [20, 21]. In light of this event, we conducted chromatin immunoprecipitation (ChIP) assay. As shown in Fig. 5A, the binding activity of STAT3 and HIF-1α to the VEGF promoter was detected under hypoxia (lanes 5-8) compared with normoxia (lanes 1-4). Notably, BA treatment suppressed the binding of STAT3 and HIF-1α to VEGF promoter in hypoxic condition (lanes 9-12).

In order to confirm the critical role of STAT3 in anti-angiogenic regulation of BA in hypoxic PC-3 cells, STAT3 siRNA transfection was carried out in PC-3 cells. Treatment with either BA or STAT3 siRNA reduced the production of VEGF by 39.6% and 45.9% respectively, compared with untreated control. Furthermore, BA treatment significantly reduced VEGF production by 63.25% in STAT3 siRNA-transfected PC-3 cells (Fig. 5B). Western blotting revealed that siRNA for STAT3, but not control, efficiently blocked STAT3 (Fig. 5B).

Discussion

Prostate cancer classified as an adenocarcinoma is the second most common malignant tumors in American men, with estimates of 192,280 new cases and approximately 27,360 deaths in 2009 [22, 23]. Betulinic acid (BA), a plant-derived pentacyclic lupane-type triterpenoid, can be extracted from various plants such as Sarracenia flava [24], Diospyros spp., Inga punctata [25], Ziziphus spp., and Vauquelinia corymbosa [26]. Several groups reported anti-cancer activity of BA in various cancers including lung, colorectal, breast, prostate and cervical cancer [27], but not normal cells [28]. Also, BA completely inhibited tumour growth without toxicity in athymic mice bearing human melanomas [6]. Moreover, anti-cancer activity of BA was exerted by inducing apoptosis in the cancer cells. For example, BA-induced apoptosis was independent of p53 in neuroectodermal tumor [29] and melanoma cells [30].

In neuroblastoma cells, BA induced apoptosis through loss of the mitochondrial membrane potential, reactive oxygen species (ROS) production and caspase activation [31]. Interestingly, Karna and colleagues recently reported that BA inhibited the expression of HIF-1α and vascular endothelial...
growth factor (VEGF) in human endometrial cancer cells [32]. However, the regulatory mechanisms whereby BA inhibits angiogenesis are not fully understood. In the present study, we found that BA suppressed hypoxia-mediated protein accumulation, transcriptional activation and nuclear localization of HIF-1α in PC-3 cells. Consistent with the results of Karna’s paper, our data also showed that BA significantly inhibited VEGF secretion and protein expression in hypoxic PC-3 cells. Additionally, in vitro tube formation assay further confirmed anti-angiogenic effect of BA in hypoxic PC-3 cells.

Recently, Niu and colleagues suggested that constitutively activated STAT3 up-regulated VEGF and induced tumor angiogenesis [20]. Also, Wei and colleagues reported that STAT3 activation regulates the expression of VEGF and human pancreatic cancer angiogenesis. Furthermore, several papers described the role of STAT3 as a potential modulator of HIF-1α-induced VEGF signaling in cancer cells [4,33]. In this regard, the effect of BA on STAT3 and HIF-1α activation was examined in hypoxic PC-3 cells in our study. Consistent with the evidences by Pandey and colleagues that BA suppressed STAT3 activation in multiple myeloma cells [13], BA prevented hypoxia-induced tyrosine phosphorylation, DNA binding activity and nuclear translocalization of STAT3, suggesting the inhibitory effect of BA on STAT3 activation.

VEGF promoter contains various transcription factor binding sites including STAT3 [20] as well as HIF-1 [34]. Physical interaction of STAT3 with HIF-1 controls VEGF transcriptional activation by their binding to the VEGF promoter [4]. In our study, hypoxia promoted the binding of STAT3 and HIF-1α to the VEGF promoter in PC-3 cells. In contrast, BA remarkably inhibited the binding of STAT3 and HIF-1α to the VEGF promoter site under hypoxic condition. Additionally, silencing STAT3 using its specific siRNA significantly enhanced BA-mediated inhibition of VEGF.
production, implying the involvement of STAT3 in anti-angiogenic regulation of BA in hypoxic PC-3 cells. Similar to our study, Gariboldi and colleagues reported that NVP-AEW541, a IGFR1 inhibitor, disrupted IGF/STAT3/HIF1 pathway in human glioblastoma cells [35]. Leeman-Neill and colleagues also reported that Guggulsterone inhibited STAT3 and HIF-1α and suggested a biologic rationale for further clinical investigation BA for human head and neck squamous cell carcinoma (HNSCC) therapy [36].

Collectively, our data demonstrate that BA suppressed expression and transactivation of hypoxia-induced HIF-1α, STAT3, VEGF as well as capillary tube formation in PC-3 cells. It is noteworthy that anti-cancer activity of BA is exerted by inhibiting angiogenesis via inhibition of binding of STAT3 and HIF-1α to the VEGF promoter in PC-3 cells. Thus, our findings suggest that BA can be a potent anti-angiogenic agent by targeting STAT3/HIF-1α/VEGF signaling for prostate cancer therapy.

### Materials and Methods

#### Compounds

Betulinic acid (BA) (Figure 1) was purchased from Sigma-Aldrich (St. Louis, MO) and dissolved in dimethyl sulfoxide (DMSO) as a 10 mM stock solution for experimental use.

#### Cell culture

Human prostate cancer cell line PC-3 was obtained from American Type Culture Collection (ATCC, Rockville, MD) and maintained in RPMI1640 (Welgene, Daegu, Korea) supplemented with 10% fetal bovine serum and 1% antibiotic-antimyotic solution. Human umbilical vein endothelial cells (HUVECs) were isolated from fresh human umbilical cord vein and maintained in EBM-2 (Lonza, Valais, Switzerland) supplemented with 2% FBS, 0.04% hydrocortisone, 0.1% VEGF, 0.1% IGF-1, 0.4% hFGF-B, 0.1% hEGF, 0.1% ascorbic acid, and 1% heparin.

#### Hypoxia induction

Cells were incubated in anaerobic incubator at 94% N₂, 5% CO₂, and 1% O₂ (Thermo scientific, Rockford, IL) as previously described [37].

#### Cytotoxicity assay

To evaluate cytotoxicity of BA, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed as previously described [38]. PC-3 cells were plated onto 96-well microplates at a density of 1×10⁴ cells per well and exposed to various concentrations of BA (0, 12.5, 25, 50 or 100 µM) for 24 h. MTT solution (1 mg/ml) (Sigma-Aldrich) was added onto each well and incubated for 2 h at 37°C. Extraction buffer (20% SDS and 50% dimethylformamide) was then added and optical density (OD) was measured using microplate reader (Tecan Austria GmbH, Groedig, Austria) at 570 nm. Cell viability was calculated as a percentage of viable cells in BA-treated group versus untreated control by following equation.

\[
\text{Cell viability (%)} = \frac{\text{OD (BA)} - \text{OD (Blank)}}{\text{OD (Control)} - \text{OD (Blank)}} \times 100
\]
Western blot analysis

Whole-cell extracts were prepared using lysis buffer [50 mM Tris (pH 7.5), 150 mM NaCl, 1% triton X-100, 0.01% SDS, 1 mM EDTA (pH 8.0) and protease inhibitor cocktail tablets (Roche Applied Science, Indianapolis, IN)]. Nuclear and cytoplasmic extracts were obtained by fractionated by using NE-PER nuclear and cytoplasmic extraction reagents (Thermo scientific, Rockford, IL). Protein samples were separated on 10% SDS-PAGE gel and transferred to a nitrocellulose membrane. The membrane was blocked in 5% nonfat skim milk, and probed with primary antibodies for HIF-1α (1:500, Gene Tex, Irvine, CA), STAT3 (1:1000, Cell Signaling, Danvers, MA), phospho-STAT3 (1:500, Cell Signaling, Danvers, MA), VEGF (1:500, Santa Cruz Biotechnologies, Santa Cruz, CA) and β-actin (Sigma, St. Louis, MO) overnight at 4°C. The membranes were exposed to HRP-conjugated secondary antibodies for 2 h at room temperature and protein expression was detected by using enhanced chemiluminescence (ECL) Western blotting detection reagent (GE Health Care Bio-Sciences, Piscataway, NJ).

HIF-1α transcription activity assay

HIF-1α transcriptional activity was analyzed by HIF-1α transcription factor assay using TransAM HIF-1 transcription factor assay kit (Active Motif, Carlsbad, CA) according to the manufacturer’s instructions. Briefly, nuclear extracts were added onto 96-well microplate coated with oligonucleotides containing hypoxia response element (HRE) (5’-TACGTGCT-3’) from the erythropoietin (EPO) gene. HIF dimers present in nuclear extracts

Figure 4. Effect of betulinic acid (BA) on hypoxia-induced angiogenesis. (A and B) PC-3 cells were treated with 0, 5 or 10 μM BA for 24 h. (A) VEGF levels in the culture supernatants were measured by using a Quantikine VEGF ELISA kit. (B) Cell lysates were prepared and subjected to Western blotting to determine VEGF expression. Graphs represent relative band intensities of VEGF/β-actin. Data represent means ± S.D. **, p<0.01 vs normoxia control, and *, p<0.05 and **, p<0.01 vs hypoxia control. (C) HUVECs were treated with VEGF (20 ng/ml) as positive control or the culture supernatant from PC-3 cells treated with or without BA (10 μM) under normoxia or hypoxia. Tube formation assay was performed using growth factor reduced Matrigel. Cells were fixed with Diff-Quick solution, photographed randomly under an Axiolight S 100 light microscope at ×100 magnification and counted.

doi:10.1371/journal.pone.0021492.g004
bind with high specificity to this response element and are subsequently detected with an antibody directed against HIF-1α. Addition of a secondary antibody conjugated to horseradish peroxidase (HRP) provides a sensitive colorimetric readout that is easily quantified by spectrophotometry. Values are expressed as optical density (OD) at 450 nm with a reference wavelength of 655 nm.

**Immunocytochemistry**

PC-3 cells were seeded on 4-chamber slides at a density of 3×10⁴ cells per chamber and treated either with or without BA (10 μM) under hypoxia as previously described [37]. The cells were fixed in 4% formaldehyde solution for 10 min at room temperature and blocked in blocking buffer (10% BSA/Triton X-100 in PBS) containing 6% horse serum for 1 h at room temperature. The slides were incubated with anti-STAT3 (1:100) antibody overnight at 4°C and then probed with anti-mouse or rabbit biotinylated antibodies (Vector Labs, Burlingame, CA) for 1.5 h at room temperature. The expression was detected by using Vector ABC complex/HRP kit (Vector Labs, Burlingame, CA) and color-developed with 3,3'-diaminobenzidine tetrahydrochloride in dark. The specimens were then counterstained with hematoxylin-eosin (Sigma-Aldrich, St. Louis, MO) and analyzed under a microscope (Leica Microsystems Res., Wetzlar, Germany).

**Electrophoretic mobility shift assay (EMSA)**

The STAT3-DNA binding was analyzed by electrophoretic mobility shift assay (EMSA) using Gelshift Chemiluminescent

---

**Figure 5. Effect of betulinic acid (BA) on STAT3 binding on the VEGF promoter in hypoxic PC-3 cells.** (A) PC-3 cells were treated with or without BA (10 μM) under normoxia or hypoxia for 4 h. The immunoprecipitated DNA with rabbit normal IgG, HIF-1α or STAT3 antibody was amplified by PCR analysis for VEGF promoter. (B) Cells were transiently transfected with siRNA for scramble or STAT3 for 24 h and treated with or without BA (10 μM) for 18 h under hypoxia. VEGF levels in the culture supernatants were measured by using a Quantikine VEGF-ELISA kit. Data represent means ± S.D. #, p<0.05 vs control, and *, p<0.05 vs control siRNA. Cell lysates were subjected to Western blotting for phospho-STAT3, STAT3 and HIF-1α. doi:10.1371/journal.pone.0021492.g005
EMSA kit (Active Motif, Carlsbad, CA) as previously described [39]. Briefly, nuclear extracts were prepared from aneuploidy-treated cells and incubated with STAT3 consensus oligonucleotides (5′-CTT CAT TTC CGG TAA ATC CCT AAA GCT-3′) (Santa Cruz Biotechnologies, Santa Cruz, CA). The DNA-protein complex formed was separated from free oligonucleotides on 5% native polyacrylamide gels. Chemiluminescent detection was performed using ECL reagents according to the vendor’s protocols (GE Health Care Bio-Sciences, Piscataway, NJ).

In vitro tube formation assay

In vitro tube formation assay was performed as previously described [40]. Matrigel (BD) was added on 24-well plates and polymerized by incubating for 1 h at 37°C. HUVECs were seeded onto Matrigel-coated plates and incubated in EBM-2 supplement-extended with VEGF (20 ng/ml) or the supernatant from PC-3 cells treated with BA (0 or 10 μM) under normoxia or hypoxia for 24 h. After 8 h incubation, cells were fixed with 4% formaldehyde and randomly chosen fields were photographed under an Axiovert S 100 light microscope (Carl Zeiss, Weimar, Germany) at 100× magnification.

Enzyme-linked immunosorbent assay (ELISA) for VEGF

PC-3 cells were plated onto 60-mm dishes at a density of 1×10^6 cells/plate and incubated in the absence or presence of BA (10 μM) under normoxia or hypoxia for 24 h. VEGF level in the supernatant was measured by using human VEGF ELISA kit according to the manufacturer’s protocol (Biosource International Inc., Camarillo, CA).

Chromatin immunoprecipitation (ChIP) assay

PC-3 cells were plated onto 100-mm dishes at a density of 1.5×10^5 cells/dish, treated with BA for 4 h under normoxic or hypoxic condition and then 1% formaldehyde and 0.125 M glycine. Soluble chromatin were isolated by using EZ-Enzyme chromatin prep kit (Millipore, Billerica, MA) and immunoprecipitated with antibodies of normal rabbit IgG (EMD biosciences, Gibbstown, NJ), HIF-1α or STAT3. Histone/DNA crosslinks were reversed by adding 5 M NaCl at 65°C for 4 h, followed by phenol/chloroform extraction and ethanol precipitation. PCR reaction was performed to amplify VEGF promoter using ChIP primers (sense 5′-AGACTCCACAGTGACATACGTG-3′ and antisense 5′-AGTGTTGCTCCCTGCACAATG-3′).

siRNA transfection

PC-3 cells were transiently transfected with scramble or STAT3 siRNA (Santa Cruz biotechnology, Santa Cruz, CA) at 50 nM by using INTERFERin siRNA transfection reagent (Polyplus-transfection Inc., New York, NY). After incubation for 24 h, the cells were treated with BA and maintained for 18 h under hypoxia.

Statistical analysis

All data were expressed as means ± S.D. Statistical significance was analyzed by student’s t-test.

Author Contributions

Conceived and designed the experiments: JS H-JeL S-JJ S-HK. Performed the experiments (Cytotoxicity assay, Western blotting, HIF-1α transactivation, IHC, tube formation assay, ELISA and ChiP assay): JS DBJ. Performed the experiments (EMSA): HHJ. Analyzed the data: JS H-JeL H-Ju E-OL SGL BSS SHC SGK KSA. Wrote the paper: JS S-JJ S-HK.

References

1. Bowman T, Garcia R, Turkson J, Jove R (2000) STATs in oncogenesis. Oncogene 19: 2474–2485.
2. Aggarwal BB, Sehi G, Ahn KS, Sandur SK, Pandey MK, et al. (2006) Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci 1091: 151–169.
3. See Koh M, Spivak-Kroizman TR, Powis G (2008) HIF-1 regulation: not so easy come, easy go. Trends Biochem Sci 33: 526–534.
4. Jung JE, Lee HG, Gho JH, Chung DH, Youn SH, et al. (2005) STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal cell carcinoma cells. Fasebj J 19: 1296–1298.
5. Jung JE, Kim HS, Lee CS, Shin VJ, Kim YN, et al. (2008) STAT3 inhibits the degradation of HIF-1α/α p by VHL-mediated ubiquitination. Exp Mol Med 40: 479–485.
6. Pisha E, Chai H, Lee IS, Chagwedera TE, Farnsworth NR, et al. (1995) Betulinic acid induces apoptosis and inhibits hedgehog signalling in rhabdomyosarcoma. Cancer Res 55: 3673–3679.
7. Mullauer FB, Kessler JH, de Roo GM, Medema JP (2007) Broad in vitro efficacy of betulinic acid induces apoptosis and inhibits hedgehog signaling in rhabdomyosarcoma. Cancer Res 67: 5193–5199.
8. Maluf KA, Mok CC, Lee IS, Chagwedera TE, Farnsworth NR, et al. (1995) In vitro tube formation assay was performed as previously described according to the manufacturer’s protocol (Biosource International Inc., Camarillo, CA).
9. Mukherjee PK, Saha K, Das J, Pal M, Saha BP (1997) Studies on the anti-infectious activity of rhizomes of Nelumbo nucifera. Planta Med 63: 140–146.
10. Elmore S, Lee DH, An JH, Kang YJ, Kim YH, et al. (2008) STAT3 inhibits HIF-1α degradation by pVHL-mediated ubiquitination. Exp Mol Med 40: 479–485.
28. Zuco V, Supino R, Righetti SC, Cleris L, Marchesi E, et al. (2002) Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells. Cancer Lett 175: 17–25.
29. Kieber M, Strasberg RM (1986) Induction of p53 without increase in p21WAF1 in betulinic acid-mediated cell death is preferential for human metastatic melanoma. DNA Cell Biol 17: 399–406.
30. Selzer E, Pimentel E, Wacheck V, Schlegel W, Pehamberger H, et al. (2000) Effects of betulinic acid alone and in combination with irradiation in human melanoma cells. J Invest Dermatol 114: 935–940.
31. Fudla S, Friesen C, Los M, Scaffidi C, Mier W, et al. (1997) Betulinic acid triggers CD95 (APO-1/Fas) and p55-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res 57: 4956–4964.
32. Karma E, Suska L, Palka JA (2010) Betulinic acid inhibits the expression of hypoxia-inducible factor 1 alpha and vascular endothelial growth factor in human endometrial adenocarcinoma cells. Mol Cell Biochem 340: 15–20.
33. Xu Q, Briggs J, Park S, Niu G, Kortylewski M, et al. (2005) Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 24: 5552–5560.
34. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, et al. (1996) Activation of vascular endothelial growth factor gene transcription by Hypoxia-inducible factor 1. Mol Cell Biol 16: 4604–4613.
35. Gariboldi MB, Ravizza R, Monti E (2010) The IGFR1 inhibitor NVP-AEW541 disrupts a pro-survival and pro-angiogenic IGF-STAT3-HIF1 pathway in human glioblastoma cells. Biochem Pharmacol 80: 455–462.
36. Leeman-Neill RJ, Wheeler SE, Singh SV, Thomas SM, Seethala RR, et al. (2009) Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription 3. Carcinogenesis 30: 1048–1056.
37. Park KY, Lee HJ, Jeong SJ, Kim HS, Kim SH, et al. (2010) 1,2,3,4,6-Penta-O-galloyl-beta-D-glucose suppresses hypoxia-induced accumulation of hypoxia-inducible factor-1 alpha and signaling in LNCaP prostate cancer cells. Biol Pharm Bull 33: 1835–1840.
38. Kim SH, Ahn KS, Jeong SJ, Kwon TR, Jung JH, et al. (2011) Janus activated kinase 2/signal transducer and activator of transcription 3 pathway mediates icariside II-induced apoptosis in U266 multiple myeloma cells. Eur J Pharmacol 654: 10–16.
39. Choo EJ, Rhee YH, Jeong SJ, Lee HJ, Kim HS, et al. (2011) Anethole exerts antineoplastic activity via inhibition of matrix metalloproteinase 2/9 and AKT1/mitogen-activated kinase/nuclear factor kappa B signaling pathways. Biol Pharm Bull 34: 41–46.
40. Lee HJ, Kim SA, Lee HJ, Jeong SJ, Han I, et al. (2010) Paeonol oxime inhibits hFGF-induced angiogenesis and reduces VEGF levels in fibrosarcoma cells. PLoS One 5: e12358.